Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific
Conferences in May and June 2024

EQS-News: Heidelberg Pharma AG / Key word(s): Conference
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific
Conferences in May and June 2024

23.05.2024 / 09:12 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific
Conferences in May and June 2024

Ladenburg, Germany, 23 May 2024 - Heidelberg Pharma AG (FSE: HPHA), a
clinical stage biotech company developing innovative Antibody Drug
Conjugates (ADCs), is pleased to announce that its management team will be
participating and presenting on its proprietary ADC technology platforms at
the following scientific conferences in May and June in 2024.

Heidelberg Pharma is an ADC specialist, developing innovative drugs based on
its proprietary ADC toolbox for the targeted and highly effective treatment
of cancer. Its lead Amanitin-based ADC product candidate, HDP-101, targeting
relapsed or refractory multiple myeloma has recently received Orphan Drug
Designation (ODD) and is currently advancing in a Phase I/IIa clinical
trial, demonstrating first signs of clinical efficacy. The Company is also
rapidly expanding its therapeutic product pipeline with a further four
programs across a variety of malignant hematologic and solid tumors.

10th Annual Oncology Innovation Forum
Date & location: 31 May 2024, Chicago, Illinois, USA
Panel: Investing in NextGen ADCs
Date: 31 May, 10:45 am CDT
Panellist: Professor Andreas Pahl, Chief Executive Officer

Presentation title: Company presentation
Date: 31 May, 02:00 pm CDT
Presenter: Professor Andreas Pahl, Chief Executive Officer

Professor Pahl will be available for one-on-one meetings, which can be
arranged via the online conference system.

ASCO Annual Meeting
Date & location: 31 May-4 June 2024, Chicago, Illinois, USA
Attending: Professor Andreas Pahl, Chief Executive Officer & Dr. András
Strassz, Chief Medical Officer

Professor Pahl and Dr. Strassz will be available for meetings.

BIO International Convention
Date & location: 3-6 June 2024, San Diego, California, USA
Attending: Dr. George Badescu, Chief Business Officer & Dr. Artjom
Wischnjow, Associate Director Business Development

Dr. Badescu and Dr. Wischnjow will be available for one-on-one meetings,
which can be arranged via the online conference system.

Jefferies Global Healthcare Conference
Date & location: 4-6 June 2024, New York, USA
Attending: Professor Andreas Pahl, Chief Executive Officer & Dr. George
Badescu, Chief Business Officer

Professor Pahl and Dr. Badescu will be available for one-on-one meetings,
which can be arranged via the online conference system.


About Heidelberg Pharma

Heidelberg Pharma develops novel drugs based on its ADC technologies for the
targeted and highly effective treatment of cancer. ADCs are antibody-drug
conjugates that combine the specificity of antibodies with the efficacy of
toxins to fight cancer. Selected antibodies are loaded with cytotoxic
compounds, the so-called payloads, that are transported into diseased cells.
Inside the cells, the toxins then unleash their effect and kill the diseased
cells.

Heidelberg Pharma is the first company to use the mushroom toxin Amanitin in
cancer therapy by exploiting the toxin's biological mechanism of action with
its innovative ATAC technology as a new therapeutic modality. It offers the
opportunity to overcome resistance of cancer cells against therapeutic
agents currently used and to eliminate dormant tumor cells, which typically
survive current therapies and are responsible for tumor relapse and
metastasis. This could lead to significant advances in cancer therapy - even
for patients who no longer respond to any other treatment. The most advanced
product candidate HDP-101 is a BCMA-ATAC for the indication multiple
myeloma, which is currently in clinical development.

In addition to Amanitin, alternative payloads also expand the ADC platform
technologies of Heidelberg Pharma to develop targeted and highly effective
ADCs for the treatment of a variety of malignant hematologic and solid
tumors.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg,
Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 /
WKN A11QVV / Symbol HPHA. More information is available at
www.heidelberg-pharma.com.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

    Contact Heidelberg Pharma AG Sylvia       IR/PR-Support MC Services AG
              Wimmer Director Corporate       Katja Arnold (CIRO) Managing
      Communications Tel.: +49 89 41 31    Director & Partner Tel.: +49 89
                          38-29 E-mail:                 210 228-40 E-mail:
              (1)investors@hdpharma.com     (1)katja.arnold@mc-services.eu
           Gregor-Mendel-Str. 22, 68526                                 1.
                          Ladenburg  1.    mailto:katja.arnold@mc-services
          mailto:investors@hdpharma.com                                .eu
   International IR/PR-Support Optimum
   Strategic Communications Mary Clark,
   Zoe Bolt, Katie Flint Tel: +44 20
   3882 9621 E-mail:
   (1)HeidelbergPharma@optimumcomms.com
   1.
   mailto:HeidelbergPharma@optimumcomms
   .com%0D

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will", "should", "future", "potential" or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, achievements, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.


---------------------------------------------------------------------------

23.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Heidelberg Pharma AG
                   Gregor-Mendel-Str. 22
                   68526 Ladenburg
                   Germany
   Phone:          +49 (0)89 41 31 38 - 0
   Fax:            +49 (0)89 41 31 38 - 99
   E-mail:         investors@hdpharma.com
   Internet:       www.heidelberg-pharma.com
   ISIN:           DE000A11QVV0
   WKN:            A11QVV
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1909263

End of News EQS News Service
---------------------------------------------------------------------------

1909263 23.05.2024 CET/CEST